The Europe Hemoglobinopathies Market would witness market growth of 5.2% CAGR during the forecast period (2022-2028).
HbS, HbD, HbE, and HbG are more frequently seen as beta-globin variants. A mutation in one beta globin component generates a blend of regular and variant hemoglobin, which creates a heterozygote state, commonly known as a trait or carrier status. Mutations in both beta globin components are because of diseases based on a homozygous or heterozygous expression. Mutations are homozygous with a synthesis of HbS in the case of sickle cell anemia (HbSS).
No matter whether it is an alpha globin or beta globin variant, the seriousness of the disease can be inconsequential or fatal. Therefore, it is necessary to identify it through newborn screening. In 2006, the Recommended Uniform Screening Panel (RUSP) added Hemoglobinopathies, specially HbSS, HbSC disease, and Hbs/beta-thalassemia, to their list.
Jointly the Maternal and Child Health Bureau of the Health Resources and Services Administration (HRSA) of the United States and the American College of Medical Genetics (ACMG) concluded that these illnesses are clinically severe and can be easily identified during newborn screening. Depending upon the severity of the disease connected with sickle cell disorder, they were added. Extreme pain, anemia, and vaso occlusive crisis, which in the end affects multiple organ systems and eventually worsens with time, are some of its symptoms.
The Pediatric and Adult hemoglobinopathy Outpatients Units of the University Hospital of Essen conducted a study and summarized the outcomes of hemoglobinopathies which was before the introduction of the general newborn screening for SCD in Germany. A total of 339 patients were diagnosed by molecular analysis, out of which 182 were minors (50.5% males) and 157 adults (75.8% females). Due to the migration and the late diagnosis of second/third-generation migrants, hemoglobinopathy is posing serious health problems in Germany.
The Germany market dominated the Europe Hemoglobinopathies Market by Country in 2021; thereby, achieving a market value of $399.3 Million by 2028. The UK market is exhibiting a CAGR of 4.3% during (2022 - 2028). Additionally, The France market would experience a CAGR of 5.9% during (2022 - 2028).
Based on Type, the market is segmented into Thalassemia, Sickle Cell Disease and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacy, Hospital Pharmacy and Online Providers. Based on Therapy, the market is segmented into Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Hemoglobinopathies Market will Hit $6 Billion by 2028, at a CAGR of 5.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Sanofi S.A., Danaher Corporation, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Merck & Co., Inc., Bristol Myers Squibb Company, Alnylam Pharmaceuticals, Inc., Emmaus Life Sciences, Inc., Biogen, Inc. and Canthera Discovery Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Thalassemia
- Sickle Cell Disease
- Others
By Distribution Channel
- Drug Stores & Retail Pharmacy
- Hospital Pharmacy
- Online Providers
By Therapy
- Monoclonal Antibody Medication
- Hydroxyurea
- ACE Inhibitors
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Sanofi S.A.
- Danaher Corporation
- Pfizer, Inc. (Global Blood Therapeutics, Inc.)
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- Alnylam Pharmaceuticals, Inc.
- Emmaus Life Sciences, Inc.
- Biogen, Inc.
- Canthera Discovery Ltd.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Hemoglobinopathies Market, by Type
1.4.2 Europe Hemoglobinopathies Market, by Distribution Channel
1.4.3 Europe Hemoglobinopathies Market, by Therapy
1.4.4 Europe Hemoglobinopathies Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and Scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Hemoglobinopathies Market by Type
3.1 Europe Thalassemia Market by Country
3.2 Europe Sickle Cell Disease Market by Country
3.3 Europe Others Market by Country
Chapter 4. Europe Hemoglobinopathies Market by Distribution Channel
4.1 Europe Drug Stores & Retail Pharmacy Market by Country
4.2 Europe Hospital Pharmacy Market by Country
4.3 Europe Online Providers Market by Country
Chapter 5. Europe Hemoglobinopathies Market by Therapy
5.1 Europe Monoclonal Antibody Medication Market by Country
5.2 Europe Hydroxyurea Market by Country
5.3 Europe ACE Inhibitors Market by Country
5.4 Europe Others Market by Country
Chapter 6. Europe Hemoglobinopathies Market by Country
6.1 Germany Hemoglobinopathies Market
6.1.1 Germany Hemoglobinopathies Market by Type
6.1.2 Germany Hemoglobinopathies Market by Distribution Channel
6.1.3 Germany Hemoglobinopathies Market by Therapy
6.2 UK Hemoglobinopathies Market
6.2.1 UK Hemoglobinopathies Market by Type
6.2.2 UK Hemoglobinopathies Market by Distribution Channel
6.2.3 UK Hemoglobinopathies Market by Therapy
6.3 France Hemoglobinopathies Market
6.3.1 France Hemoglobinopathies Market by Type
6.3.2 France Hemoglobinopathies Market by Distribution Channel
6.3.3 France Hemoglobinopathies Market by Therapy
6.4 Russia Hemoglobinopathies Market
6.4.1 Russia Hemoglobinopathies Market by Type
6.4.2 Russia Hemoglobinopathies Market by Distribution Channel
6.4.3 Russia Hemoglobinopathies Market by Therapy
6.5 Spain Hemoglobinopathies Market
6.5.1 Spain Hemoglobinopathies Market by Type
6.5.2 Spain Hemoglobinopathies Market by Distribution Channel
6.5.3 Spain Hemoglobinopathies Market by Therapy
6.6 Italy Hemoglobinopathies Market
6.6.1 Italy Hemoglobinopathies Market by Type
6.6.2 Italy Hemoglobinopathies Market by Distribution Channel
6.6.3 Italy Hemoglobinopathies Market by Therapy
6.7 Rest of Europe Hemoglobinopathies Market
6.7.1 Rest of Europe Hemoglobinopathies Market by Type
6.7.2 Rest of Europe Hemoglobinopathies Market by Distribution Channel
6.7.3 Rest of Europe Hemoglobinopathies Market by Therapy
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Sanofi S.A.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Trials and Approvals:
7.3 Danaher Corporation
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.4 Pfizer, Inc. (Global Blood Therapeutics, Inc.)
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional & Segmental Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Approvals and Trials:
7.5 Merck & Co., Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expenses
7.6 Bristol Myers Squibb Company
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.7 Alnylam Pharmaceuticals, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expense
7.8 Emmaus Life Sciences, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expenses
7.9 Biogen, Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expense
7.10. Canthera Discovery Ltd.
7.10.1 Company Overview
TABLE 1 Europe Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 2 Europe Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 3 Europe Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 4 Europe Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 5 Europe Thalassemia Market by Country, 2018 - 2021, USD Million
TABLE 6 Europe Thalassemia Market by Country, 2022 - 2028, USD Million
TABLE 7 Europe Sickle Cell Disease Market by Country, 2018 - 2021, USD Million
TABLE 8 Europe Sickle Cell Disease Market by Country, 2022 - 2028, USD Million
TABLE 9 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 10 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 11 Europe Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 12 Europe Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 13 Europe Drug Stores & Retail Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 14 Europe Drug Stores & Retail Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 15 Europe Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 16 Europe Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 17 Europe Online Providers Market by Country, 2018 - 2021, USD Million
TABLE 18 Europe Online Providers Market by Country, 2022 - 2028, USD Million
TABLE 19 Europe Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 20 Europe Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 21 Europe Monoclonal Antibody Medication Market by Country, 2018 - 2021, USD Million
TABLE 22 Europe Monoclonal Antibody Medication Market by Country, 2022 - 2028, USD Million
TABLE 23 Europe Hydroxyurea Market by Country, 2018 - 2021, USD Million
TABLE 24 Europe Hydroxyurea Market by Country, 2022 - 2028, USD Million
TABLE 25 Europe ACE Inhibitors Market by Country, 2018 - 2021, USD Million
TABLE 26 Europe ACE Inhibitors Market by Country, 2022 - 2028, USD Million
TABLE 27 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 28 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 29 Europe Hemoglobinopathies Market by Country, 2018 - 2021, USD Million
TABLE 30 Europe Hemoglobinopathies Market by Country, 2022 - 2028, USD Million
TABLE 31 Germany Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 32 Germany Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 33 Germany Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 34 Germany Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 35 Germany Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 36 Germany Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 37 Germany Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 38 Germany Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 39 UK Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 40 UK Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 41 UK Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 42 UK Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 43 UK Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 44 UK Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 45 UK Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 46 UK Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 47 France Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 48 France Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 49 France Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 50 France Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 51 France Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 52 France Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 53 France Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 54 France Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 55 Russia Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 56 Russia Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 57 Russia Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 58 Russia Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 59 Russia Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 60 Russia Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 61 Russia Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 62 Russia Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 63 Spain Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 64 Spain Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 65 Spain Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 66 Spain Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 67 Spain Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 68 Spain Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 69 Spain Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 70 Spain Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 71 Italy Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 72 Italy Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 73 Italy Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 74 Italy Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 75 Italy Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 76 Italy Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 77 Italy Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 78 Italy Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 79 Rest of Europe Hemoglobinopathies Market, 2018 - 2021, USD Million
TABLE 80 Rest of Europe Hemoglobinopathies Market, 2022 - 2028, USD Million
TABLE 81 Rest of Europe Hemoglobinopathies Market by Type, 2018 - 2021, USD Million
TABLE 82 Rest of Europe Hemoglobinopathies Market by Type, 2022 - 2028, USD Million
TABLE 83 Rest of Europe Hemoglobinopathies Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 84 Rest of Europe Hemoglobinopathies Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 85 Rest of Europe Hemoglobinopathies Market by Therapy, 2018 - 2021, USD Million
TABLE 86 Rest of Europe Hemoglobinopathies Market by Therapy, 2022 - 2028, USD Million
TABLE 87 Key Information – Abbott Laboratories
TABLE 88 Key Information – Sanofi S.A.
TABLE 89 Key Information – Danaher Corporation
TABLE 90 Key Information – Pfizer, Inc.
TABLE 91 KEY INFORMATION - Merck & Co., Inc.
TABLE 92 Key Information – Bristol Myers Squibb Company
TABLE 93 Key Information – Alnylam Pharmaceuticals, Inc.
TABLE 94 Key Information – Emmaus Life Sciences, INC.
TABLE 95 Key Information – Biogen, Inc.
TABLE 96 Key Information – Canthera Discovery Ltd.
List of Figures
FIG 1 Methodology for the research
FIG 2 Swot analysis: Abbott laboratories